Payment overview · 2025
General Payments
$512.62
6 reported records · 4 companies
Healthcare provider profile · identity verified
Anthony B Cifelli, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MORRIS PLAINS, NJ · NPI 1245228451
Verified facts
What the public records show
CMS Open Payments records show Anthony B Cifelli, M.D. received $512.62 in general payments during 2025 across 6 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.52 | 47.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $126.63 | 24.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.73 | 24.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.74 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $512.62 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $225.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $126.63 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $124.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 381 | 104 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 326 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 318 | 82 |
| Alprazolam | Alprazolam | 285 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 274 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 54 |
| Metformin Hcl | Metformin Hcl | 211 | 60 |
| Losartan Potassium | Losartan Potassium | 210 | 55 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 184 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 33 |
| Lisinopril | Lisinopril | 163 | 46 |
| Lorazepam | Lorazepam | 146 | 30 |
| Ozempic | Semaglutide | 145 | 17 |
| Gabapentin | Gabapentin | 142 | 39 |
| Omeprazole | Omeprazole | 141 | 46 |
| Clonazepam | Clonazepam | 132 | 31 |
| Simvastatin | Simvastatin | 128 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 120 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 34 |
| Methylprednisolone | Methylprednisolone | 109 | 92 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 101 | 28 |
| Carvedilol | Carvedilol | 94 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 23 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 67 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | suppressed |
| Potassium Chloride | Potassium Chloride | 66 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 28 |
| Famotidine | Famotidine | 64 | 20 |
| Glimepiride | Glimepiride | 63 | 11 |
| Glipizide | Glipizide | 62 | 16 |
| Finasteride | Finasteride | 61 | 14 |
| Prednisone | Prednisone | 61 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 13 |
| Synthroid | Levothyroxine Sodium | 56 | 17 |
| Trazodone Hcl | Trazodone Hcl | 55 | 14 |
| Jardiance | Empagliflozin | 54 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 52 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 17 |
| Azithromycin | Azithromycin | 49 | 46 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | suppressed |
| Diazepam | Diazepam | 45 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 14 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 42 | 35 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 40 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 39 | 21 |
| Ramipril | Ramipril | 39 | 11 |
| Sertraline Hcl | Sertraline Hcl | 39 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | 29 |
| Colchicine | Colchicine | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Furosemide | Furosemide | 35 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 21 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Testosterone | Testosterone | 18 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $512.62 · 6 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, GEMTESA, Ozempic, QULIPTA | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error